A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF SUNITINIB IN METASTATIC COLORECTAL CANCER PATIENTS RECEIVING IRINOTECAN, 5-FLUOROURACIL AND LEUCOVORIN (FOLFIRI) AS FIRST LINE TREATMENT

Update Il y a 4 ans
Reference: EUCTR2007-000325-21

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To demonstrate that the combination of FOLFIRI plus sunitinib is superior to FOLFIRI plus placebo in prolonging the progression-free survival (PFS) in the first-line treatment of patients with metastatic colorectal cancer.


Inclusion criteria

  • first-line treatment of patients with metastatic colorectal cancer